The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11,998.00
Bid: 11,998.00
Ask: 12,000.00
Change: -30.00 (-0.25%)
Spread: 2.00 (0.017%)
Open: 12,052.00
High: 12,094.00
Low: 11,956.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE: EU regulator "firmly convinced" of AstraZeneca benefits

Tue, 16th Mar 2021 18:01

(Alliance News) - Comments by the European Medicines Agency, or EMA, on the AstraZeneca PLC vaccine are "encouraging," French President Emmanuel Macron and Italian Prime Minister Mario Draghi said Tuesday.

"Today's preliminary statements from EMA are encouraging," they said in a statement released by Draghi's office, which added that they are ready to resume AstraZeneca jabs if the vaccine is cleared by the EU regulator.

The EU's drug regulator said earlier Tuesday it remained "firmly convinced" of the benefits of AstraZeneca's coronavirus vaccine despite several countries suspending its use over blood clot fears.

"We are still firmly convinced that the benefits of the AstraZeneca vaccine in preventing Covid-19 with its associated risk of hospitalisation and death outweigh the risk of these side effects," European Medicines Agency chief Emer Cooke told an online press conference.

"At present there is no indication that vaccination has caused these conditions. They have not come up in the clinical trials and they are not listed as known or expected side effects," Cooke added.

Clinical trials had shown "very small numbers of blood clot developments", she added.

Some 30 cases of blood clots had been reported to the EMA by March 10 among almost five million people vaccinated, but additional cases had been reported over the weekend, Cooke said.

According to AstraZeneca, about 17 million people in the EU and the UK have received a dose of the vaccine, with fewer than 40 cases of blood clots reported to date.

The Amsterdam-based EMA's safety committee was meeting Tuesday to assess new information and would reach a conclusion at a special meeting on Thursday, Cooke said. 

They would then "advise us on whether there are any further actions that need to be taken", she said, without specifying what the measures could be.

Several European countries, including Germany, France, Italy, Spain, Denmark and Norway, have suspended rollout of the vaccine.

World Health Organization experts are also meeting on Tuesday to discuss the vaccine.

The EMA approved the AstraZeneca vaccine for people of all ages on January 29.

But its rollout was troubled from the start, with several countries initially saying it should not be used on older people.

Seaprately, EU's medicines regulator is probing serious side effects of "all vaccines".

"We are looking at adverse events associated with all vaccines," Cooke said when asked if it was probing the Pfizer Inc-BioNTech SE and Moderna Inc vaccines as well, following reports of clotting with those jabs in the US.

"At the moment the correct focus, because of the reported incidents in Europe, is on AstraZeneca," she told a press conference.

"But we have looked at the background rates of all the vaccines currently in circulation and it looks like there are similar numbers coming in across the world. But that is something that will have to be evaluated by our (safety) committee."

source: AFP

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
1 Dec 2023 08:52

LONDON MARKET OPEN: Miners give FTSE 100 boost thanks to China PMI

(Alliance News) - Stock prices in London opened higher on Friday, with the FTSE 100 boosted by mining stocks.

Read more
1 Dec 2023 08:33

AstraZeneca discontinues two phase III evidence trials for Lokelma

(Alliance News) - AstraZeneca on Friday said it has decided to discontinue the Stabilize-CKD and Dialize-outcomes phase III trials for Lokelma, citing increased enrolment timelines.

Read more
1 Dec 2023 08:01

AstraZeneca calls off two phase III trials into hyperkalaemia treatment

(Sharecast News) - Drugmaker AstraZeneca has called off two phase III trials on its hyperkalaemia treatment after a series of logistical challenges.

Read more
1 Dec 2023 07:41

LONDON BRIEFING: Stocks called higher; UK house prices fall annually

(Alliance News) - Stocks in London are called to open higher on Friday, following data from Nationwide showing that the annual pace of UK house price decline slowed in November.

Read more
27 Nov 2023 16:12

London close: Stocks start week in subdued state

(Sharecast News) - London's financial markets saw a somewhat subdued performance on Monday, as concerns regarding the Chinese economy cast a shadow over investor sentiment.

Read more
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.